Publications by authors named "Laura D Porter"
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024.
J Natl Compr Canc Netw
September 2024
Article Synopsis
- * These guidelines are designed to support physicians in making informed decisions about CRC screening for patients who do not have specific genetic syndromes.
- * Recent updates include insights on both primary and secondary CRC prevention, particularly addressing when to start screening for average-risk individuals and those with a relevant personal history of cancer.
The Importance of Patient Engagement to Improve Healthcare Research and Safety.
Glob J Qual Saf Healthc
May 2022
Patient Advocates and Researchers as Partners in Cancer Research: A Winning Combination.
Am Soc Clin Oncol Educ Book
May 2023
Article Synopsis
- Inclusion of advocates in research is now mandated by many international funding agencies, emphasizing their crucial role.
- Advocates are involved across all research areas, including basic cancer research and clinical trials, enhancing collaboration despite the challenges faced.
- The text aims to define patient advocacy, detail advocate engagement, and provide insights into training programs that facilitate partnership between advocates and researchers.
Article Synopsis
- The purpose of the text is to raise awareness and provide guidance on managing immune-related adverse events (irAEs) for patients undergoing immune checkpoint inhibitor (ICPi) therapy.
- A diverse panel of medical experts conducted a systematic review of relevant literature from 2017 to 2021 to formulate updated management recommendations based on both evidence and expert consensus.
- Recommendations include continuing ICPi therapy with monitoring for mild toxicities, suspending treatment for moderate toxicities, and using corticosteroids for more severe cases, with a recommendation for permanent discontinuation for severe toxicities, except in specific controllable conditions.
Purpose: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
Methods: A multidisciplinary panel of medical oncology, neurology, hematology, emergency medicine, nursing, trialists, and advocacy experts was convened to develop the guideline. Guideline development involved a systematic literature review and an informal consensus process.
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process.
View Article and Find Full Text PDF